We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




AI Model Accurately Shows Presence and Location of Cancer in Pathological Images

By LabMedica International staff writers
Posted on 15 Aug 2022

It is usually necessary to accurately mark the location of the cancer site in pathological images to solve the problems involved with zoning that indicates the location information of cancer, which takes a long time and therefore increased cost. More...

Existing deep learning models need to construct a dataset, in which the location of the cancer was accurately drawn, to specify the cancer site. Now, researchers have developed a weakly supervised deep learning model that can accurately show the presence and location of cancer in pathological images based only on data where the cancer is present. The deep learning model improves efficiency and is expected to make a significant contribution to the relevant research field.

Scientists at Daegu Gyeongbuk Institute of Science and Technology (DGIST, Daegu, Korea) developed the weakly supervised learning model that zones cancer sites with only rough data such as 'whether the cancer in the image is present or not' is under active study. However, there would be a significant deterioration in performance if the existing weakly supervised learning model is applied to a huge pathological image dataset where the size of one image is as large as a few gigabytes. To solve this problem, the researchers attempted to improve performance by dividing the pathological image into patches, although the divided patches lose the correlation between the location information and each split data, which means that there is a limit to using all of the available information.

In response, the research team discovered a technique of segmenting down to the cancer site solely based on the learned data indicating the presence of cancer by slide. The team developed a pathological image compression technology that first teaches the network to effectively extract significant features from the patches through unsupervised contrastive learning and uses this to detect the main features while maintaining each location information to reduce the size of the image while maintaining the correlation between the patches. Later, the team developed a model that can find the regions that are highly likely to have cancer from the compressed pathology images by using a class activation map and zone all of these regions from the entire pathology images using a pixel correlation module (PCM). The newly developed deep learning model showed a dice similarity coefficient (DSC) score of up to 81-84 only with the learning data with slide-level cancer labels in the cancer zoning problem. It significantly exceeded the performance of previously proposed patch level methods or other weakly supervised learning techniques (DSC score: 20 - 70).

“The model developed through this study has greatly improved the performance of weakly supervised learning of pathological images, and it is expected to contribute to improving the efficiency of various studies requiring pathological image analysis,” said Professor Park Sang-Hyun of the Department of Robotics and Mechatronics Engineering at DGIST. “If we can improve the related technology further in the future, it will be possible to use it universally for various medical image zoning issues.”

Related Links:
DGIST 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: AlzoSure Predict is designed to help clinicians assess the likelihood of Alzheimer’s disease progression in patients with mild cognitive impairment. (Photo courtesy of Diadem)

Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch

Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60–70% of cases worldwide. Its progressive effects on memory, thinking, behavior, and daily functioning underscore... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.